{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:29:23Z","timestamp":1793053763770,"version":"4.5.0"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>cyclin-dependent kinase 9 (CDK9) A key regulator of transcriptional elongation influences the transcription of oncogenes and anti-apoptotic proteins. Within the context of the positive transcription elongation factor b (P-TEFb) complex, CDK9 facilitates the phosphorylation of the C-terminal domain of RNA polymerase II. It also contributes to epigenetic regulation by phosphorylating histones and altering chromatin accessibility, thereby sustaining the transcription of oncogenic programs. This mechanism initiates the transcription of genes that are crucial for the proliferation and survival of cancer cells. A variety of hematological malignancies, including acute myeloid leukemia (AML), multiple myeloma (MM), and diffuse large B-cell lymphoma (DLBCL), have been associated with dysregulated CDK9 activity, which sustains oncogene expression and contributes to resistance to treatment. A notable therapeutic approach focuses on the inhibition of CDK9. This method may function as a therapeutic strategy that exploits the transcriptional addiction of malignant cells to short-lived oncogenic transcripts. By targeting a central regulator of transcriptional elongation, this approach selectively disrupts the sustained expression of survival-critical proteins such as MCL-1 and MYC, thereby exposing a therapeutic vulnerability in hematologic malignancies. Promising outcomes in preclinical and early clinical studies have been achieved by developing selective and pharmacokinetically more effective CDK9 inhibitors. Candidates for the combination of conventional chemotherapeutic drugs with other targeted therapy modalities. Research findings indicate that innovative CDK9 inhibitors and the silencing of CDK9 through siRNA may drastically change the therapeutic approach to hematological malignancies, particularly for patients facing recurrence or resistance to prior treatments. This review focuses primarily on hematologic malignancies because they exhibit pronounced transcriptional addiction to short-lived super-enhancer-driven transcripts (MYC, MCL-1), making CDK9 inhibition particularly effective. In contrast, solid tumors often display greater microenvironmental heterogeneity and compensatory pathways that limit single-agent efficacy.<\/jats:p>","DOI":"10.1007\/s10238-026-02141-3","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T09:58:03Z","timestamp":1779875883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CDK9 and hematologic malignancies: pioneering novel therapeutic approaches"],"prefix":"10.1007","volume":"26","author":[{"given":"Hanie","family":"Raufi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Zahmatkesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Safaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata","family":"Bahadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Solali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"2141_CR1","doi-asserted-by":"publisher","first-page":"997","DOI":"10.18632\/oncotarget.28543","volume":"14","author":"F Zhou","year":"2023","unstructured":"Zhou F, Tang L, Le S, Ge M, Cicic D, Xie F, et al. The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies. Oncotarget. 2023;14:997\u20131008.","journal-title":"Oncotarget"},{"key":"2141_CR2","doi-asserted-by":"publisher","first-page":"116470","DOI":"10.1016\/j.bcp.2024.116470","volume":"229","author":"C Mo","year":"2024","unstructured":"Mo C, Wei N, Li T, Ahmed Bhat M, Mohammadi M, Kuang C. CDK9 inhibitors for the treatment of solid tumors. Biochem Pharmacol. 2024;229:116470.","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"2141_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S1357-2725(96)00178-1","volume":"29","author":"M Arellano","year":"1997","unstructured":"Arellano M, Moreno S. Regulation of CDK\/cyclin complexes during the cell cycle. Int J Biochem Cell Biol. 1997;29(4):559\u201373.","journal-title":"Int J Biochem Cell Biol"},{"issue":"7","key":"2141_CR4","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.cell.2016.11.034","volume":"167","author":"MP Swaffer","year":"2016","unstructured":"Swaffer MP, Jones AW, Flynn HR, Snijders AP, Nurse P. CDK substrate phosphorylation and ordering the cell cycle. Cell. 2016;167(7):1750\u201361. e16.","journal-title":"Cell"},{"issue":"15","key":"2141_CR5","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1242\/dev.091744","volume":"140","author":"S Lim","year":"2013","unstructured":"Lim S, Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development. 2013;140(15):3079\u201393.","journal-title":"Development"},{"issue":"2","key":"2141_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/nrd4504","volume":"14","author":"U Asghar","year":"2015","unstructured":"Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery. 2015;14(2):130\u201346.","journal-title":"Nat Rev Drug Discovery"},{"issue":"2","key":"2141_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/jcp.22426","volume":"226","author":"J W\u0119sierska-G\u0105dek","year":"2011","unstructured":"W\u0119sierska-G\u0105dek J, Maurer M, Zulehner N, Komina O. Whether to target single or multiple CDKs for therapy? That is the question. J Cell Physiol. 2011;226(2):341\u20139.","journal-title":"J Cell Physiol"},{"issue":"5","key":"2141_CR8","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jb\/mvm090","volume":"141","author":"Y Hirose","year":"2007","unstructured":"Hirose Y, Ohkuma Y. Phosphorylation of the C-terminal domain of RNA polymerase II plays central roles in the integrated events of eucaryotic gene expression. J Biochem. 2007;141(5):601\u20138.","journal-title":"J Biochem"},{"issue":"12","key":"2141_CR9","doi-asserted-by":"publisher","first-page":"7306","DOI":"10.1128\/MCB.17.12.7306","volume":"17","author":"C Koumenis","year":"1997","unstructured":"Koumenis C, Giaccia A. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol Cell Biol. 1997;17(12):7306\u201316.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"2141_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discov. 2020;10(3):351\u201370.","journal-title":"Cancer Discov"},{"issue":"4","key":"2141_CR11","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cell.2016.12.013","volume":"168","author":"JE Bradner","year":"2017","unstructured":"Bradner JE, Hnisz D, Young RA. Transcriptional Addiction in Cancer. Cell. 2017;168(4):629\u201343.","journal-title":"Cell"},{"issue":"7511","key":"2141_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nature13393","volume":"511","author":"N Kwiatkowski","year":"2014","unstructured":"Kwiatkowski N, Zhang T, Rahl PB, Abraham BJ, Reddy J, Ficarro SB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014;511(7511):616\u201320.","journal-title":"Nature"},{"issue":"2","key":"2141_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.cell.2013.03.036","volume":"153","author":"J Lov\u00e9n","year":"2013","unstructured":"Lov\u00e9n J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320\u201334.","journal-title":"Cell"},{"issue":"4","key":"2141_CR14","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2013.09.053","volume":"155","author":"D Hnisz","year":"2013","unstructured":"Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andr\u00e9 V, Sigova AA, et al. Super-enhancers in the control of cell identity and disease. Cell. 2013;155(4):934\u201347.","journal-title":"Cell"},{"issue":"2","key":"2141_CR15","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.cell.2013.03.035","volume":"153","author":"WA Whyte","year":"2013","unstructured":"Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell. 2013;153(2):307\u201319.","journal-title":"Cell"},{"issue":"16","key":"2141_CR16","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1101\/gad.244368.114","volume":"28","author":"CH Huang","year":"2014","unstructured":"Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, et al. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014;28(16):1800\u201314.","journal-title":"Genes Dev"},{"issue":"6","key":"2141_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/leu.2015.10","volume":"29","author":"GP Gregory","year":"2015","unstructured":"Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia. 2015;29(6):1437\u201341.","journal-title":"Leukemia"},{"issue":"13","key":"2141_CR18","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1038\/emboj.2008.121","volume":"27","author":"S Baumli","year":"2008","unstructured":"Baumli S, Lolli G, Lowe ED, Troiani S, Rusconi L, Bullock AN, et al. The structure of P-TEFb (CDK9\/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. Embo j. 2008;27(13):1907\u201318.","journal-title":"Embo j"},{"issue":"8","key":"2141_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1096\/fasebj.9.8.7768349","volume":"9","author":"SK Hanks","year":"1995","unstructured":"Hanks SK, Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 1995;9(8):576\u201396.","journal-title":"FASEB J"},{"issue":"6430","key":"2141_CR20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/363595a0","volume":"363","author":"HL De Bondt","year":"1993","unstructured":"De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim S-H. Crystal structure of cyclin-dependent kinase 2. Nature. 1993;363(6430):595\u2013602.","journal-title":"Nature"},{"issue":"4","key":"2141_CR21","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/15384101.2016.1138186","volume":"15","author":"F Morales","year":"2016","unstructured":"Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle. 2016;15(4):519\u201327.","journal-title":"Cell Cycle"},{"key":"2141_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0378-1119(03)00466-9","volume":"307","author":"SM Shore","year":"2003","unstructured":"Shore SM, Byers SA, Maury W, Price DH. Identification of a novel isoform of Cdk9. Gene. 2003;307:175\u201382.","journal-title":"Gene"},{"issue":"1","key":"2141_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/jcp.20224","volume":"203","author":"H Liu","year":"2005","unstructured":"Liu H, Herrmann CH. Differential localization and expression of the Cdk9 42k and 55k isoforms. J Cell Physiol. 2005;203(1):251\u201360.","journal-title":"J Cell Physiol"},{"key":"2141_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1742-4690-3-66","volume":"3","author":"TL Sung","year":"2006","unstructured":"Sung TL, Rice AP. Effects of prostratin on Cyclin T1\/P-TEFb function and the gene expression profile in primary resting CD4\u2009+\u2009T cells. Retrovirology. 2006;3:66.","journal-title":"Retrovirology"},{"issue":"3","key":"2141_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.molcel.2022.12.021","volume":"83","author":"JB Rodr\u00edguez-Molina","year":"2023","unstructured":"Rodr\u00edguez-Molina JB, West S, Passmore LA. Knowing when to stop: Transcription termination on protein-coding genes by eukaryotic RNAPII. Mol Cell. 2023;83(3):404\u201315.","journal-title":"Mol Cell"},{"issue":"4","key":"2141_CR26","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.cell.2019.09.018","volume":"179","author":"P Cramer","year":"2019","unstructured":"Cramer P. Eukaryotic Transcription Turns 50. Cell. 2019;179(4):808\u201312.","journal-title":"Cell"},{"issue":"12","key":"2141_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.tibs.2013.09.002","volume":"38","author":"S Gr\u00fcnberg","year":"2013","unstructured":"Gr\u00fcnberg S, Hahn S. Structural insights into transcription initiation by RNA polymerase II. Trends Biochem Sci. 2013;38(12):603\u201311.","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"2141_CR28","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41580-018-0010-5","volume":"19","author":"FX Chen","year":"2018","unstructured":"Chen FX, Smith ER, Shilatifard A. Born to run: control of transcription elongation by RNA polymerase II. Nat Rev Mol Cell Biol. 2018;19(7):464\u201378.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"2141_CR29","doi-asserted-by":"publisher","first-page":"8423","DOI":"10.1021\/cr400158h","volume":"113","author":"JL Corden","year":"2013","unstructured":"Corden JL. RNA polymerase II C-terminal domain: Tethering transcription to transcript and template. Chem Rev. 2013;113(11):8423\u201355.","journal-title":"Chem Rev"},{"issue":"19","key":"2141_CR30","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1101\/gad.824700","volume":"14","author":"P Komarnitsky","year":"2000","unstructured":"Komarnitsky P, Cho EJ, Buratowski S. Different phosphorylated forms of RNA polymerase II and associated mRNA processing factors during transcription. Genes Dev. 2000;14(19):2452\u201360.","journal-title":"Genes Dev"},{"issue":"6","key":"2141_CR31","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1002\/pro.3424","volume":"27","author":"JK Rimel","year":"2018","unstructured":"Rimel JK, Taatjes DJ. The essential and multifunctional TFIIH complex. Protein Sci. 2018;27(6):1018\u201337.","journal-title":"Protein Sci"},{"key":"2141_CR32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-biochem-052610-095910","volume":"81","author":"Q Zhou","year":"2012","unstructured":"Zhou Q, Li T, Price DH. RNA polymerase II elongation control. Annu Rev Biochem. 2012;81:119\u201343.","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"2141_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.molcel.2015.08.006","volume":"59","author":"F Coin","year":"2015","unstructured":"Coin F, Egly JM. Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor. Mol Cell. 2015;59(4):513\u20134.","journal-title":"Mol Cell"},{"issue":"4","key":"2141_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.molcel.2005.06.029","volume":"19","author":"Z Yang","year":"2005","unstructured":"Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, et al. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535\u201345.","journal-title":"Mol Cell"},{"key":"2141_CR35","doi-asserted-by":"crossref","unstructured":"Fujinaga K. P-TEFb as A Promising Therapeutic Target. Molecules. 2020;25(4):838.","DOI":"10.3390\/molecules25040838"},{"issue":"3","key":"2141_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.molcel.2006.06.014","volume":"23","author":"BM Peterlin","year":"2006","unstructured":"Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell. 2006;23(3):297\u2013305.","journal-title":"Mol Cell"},{"issue":"1","key":"2141_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.cell.2007.05.042","volume":"130","author":"MG Guenther","year":"2007","unstructured":"Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 2007;130(1):77\u201388.","journal-title":"Cell"},{"issue":"12","key":"2141_CR38","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1038\/ng.2007.21","volume":"39","author":"GW Muse","year":"2007","unstructured":"Muse GW, Gilchrist DA, Nechaev S, Shah R, Parker JS, Grissom SF, et al. RNA polymerase is poised for activation across the genome. Nat Genet. 2007;39(12):1507\u201311.","journal-title":"Nat Genet"},{"issue":"2","key":"2141_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1128\/MCB.01157-14","volume":"35","author":"TT Eifler","year":"2015","unstructured":"Eifler TT, Shao W, Bartholomeeusen K, Fujinaga K, J\u00e4ger S, Johnson JR, et al. Cyclin-dependent kinase 12 increases 3\u2019 end processing of growth factor-induced c-FOS transcripts. Mol Cell Biol. 2015;35(2):468\u201378.","journal-title":"Mol Cell Biol"},{"issue":"6266","key":"2141_CR40","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1126\/science.aad2338","volume":"350","author":"M Yu","year":"2015","unstructured":"Yu M, Yang W, Ni T, Tang Z, Nakadai T, Zhu J, et al. RNA polymerase II-associated factor 1 regulates the release and phosphorylation of paused RNA polymerase II. Science. 2015;350(6266):1383\u20136.","journal-title":"Science"},{"key":"2141_CR41","doi-asserted-by":"crossref","unstructured":"Wong RWJ, Ishida T, Sanda T. Targeting General Transcriptional Machinery as a Therapeutic Strategy for Adult T-Cell Leukemia. Molecules. 2018;23(5):1057.","DOI":"10.3390\/molecules23051057"},{"issue":"5","key":"2141_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"key":"2141_CR43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.biochi.2025.05.003","volume":"238","author":"O Puidebat","year":"2025","unstructured":"Puidebat O, Egloff S. The 7SK snRNP complex: a critical regulator in carcinogenesis. Biochimie. 2025;238:3\u20138.","journal-title":"Biochimie"},{"issue":"1","key":"2141_CR44","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1038\/s41467-026-68285-8","volume":"17","author":"Y Yang","year":"2026","unstructured":"Yang Y, Murrali MG, Galvan S, Wang Y, Stephen C, Ajjampore N, et al. HEXIM1 inter-monomer autoinhibition governs 7SK RNA binding specificity and P-TEFb inactivation. Nat Commun. 2026;17(1):1570.","journal-title":"Nat Commun"},{"issue":"20","key":"2141_CR45","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.1111\/febs.16580","volume":"290","author":"A Kotekar","year":"2023","unstructured":"Kotekar A, Singh AK, Devaiah BN. BRD4 and MYC: power couple in transcription and disease. Febs j. 2023;290(20):4820\u201342.","journal-title":"Febs j"},{"issue":"9","key":"2141_CR46","doi-asserted-by":"publisher","first-page":"107581","DOI":"10.1016\/j.isci.2023.107581","volume":"26","author":"RY Moreno","year":"2023","unstructured":"Moreno RY, Juetten KJ, Panina SB, Butalewicz JP, Floyd BM, Venkat Ramani MK, et al. Distinctive interactomes of RNA polymerase II phosphorylation during different stages of transcription. iScience. 2023;26(9):107581.","journal-title":"iScience"},{"issue":"3","key":"2141_CR47","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2022.12.006","volume":"83","author":"K Fujinaga","year":"2023","unstructured":"Fujinaga K, Huang F, Peterlin BM. P-TEFb: The master regulator of transcription elongation. Mol Cell. 2023;83(3):393\u2013403.","journal-title":"Mol Cell"},{"issue":"45","key":"2141_CR48","doi-asserted-by":"publisher","first-page":"13988","DOI":"10.1073\/pnas.1502943112","volume":"112","author":"L Pan","year":"2015","unstructured":"Pan L, Xie W, Li KL, Yang Z, Xu J, Zhang W, et al. Heterochromatin remodeling by CDK12 contributes to learning in Drosophila. Proc Natl Acad Sci U S A. 2015;112(45):13988\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2141_CR49","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1016\/j.cell.2018.09.051","volume":"175","author":"H Zhang","year":"2018","unstructured":"Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, et al. Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer. Cell. 2018;175(5):1244\u2013e5826.","journal-title":"Cell"},{"issue":"4","key":"2141_CR50","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.gendis.2018.06.003","volume":"5","author":"M Fardi","year":"2018","unstructured":"Fardi M, Solali S, Farshdousti Hagh M. Epigenetic mechanisms as a new approach in cancer treatment: An updated review. Genes Dis. 2018;5(4):304\u201311.","journal-title":"Genes Dis"},{"issue":"11","key":"2141_CR51","first-page":"1171","volume":"133","author":"EM Beauchamp","year":"2019","unstructured":"Beauchamp EM, Abedin SM, Radecki SG, Fischietti M, Arslan AD, Blyth GT, et al. Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. Blood J Am Soc Hematol. 2019;133(11):1171\u201385.","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"2141_CR52","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/13543784.2019.1678583","volume":"28","author":"DJ Lee","year":"2019","unstructured":"Lee DJ, Zeidner JF. Cyclin-dependent kinase (CDK) 9 and 4\/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach. Expert Opin Investig Drugs. 2019;28(11):989\u20131001.","journal-title":"Expert Opin Investig Drugs"},{"issue":"41","key":"2141_CR53","doi-asserted-by":"publisher","first-page":"26353","DOI":"10.18632\/oncotarget.25293","volume":"9","author":"JR G\u00f6thert","year":"2018","unstructured":"G\u00f6thert JR, Imsak R, M\u00f6llmann M, Kesper S, G\u00f6bel M, D\u00fchrsen U, et al. Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia. Oncotarget. 2018;9(41):26353\u201369.","journal-title":"Oncotarget"},{"issue":"7","key":"2141_CR54","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","volume":"106","author":"R Chen","year":"2005","unstructured":"Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005;106(7):2513\u20139.","journal-title":"Blood"},{"issue":"9","key":"2141_CR55","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1158\/1535-7163.MCT-18-1023","volume":"18","author":"T Hashiguchi","year":"2019","unstructured":"Hashiguchi T, Bruss N, Best S, Lam V, Danilova O, Paiva CJ, et al. Cyclin-dependent kinase-9 is a therapeutic target in MYC-expressing diffuse large B-cell lymphoma. Mol Cancer Ther. 2019;18(9):1520\u201332.","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2141_CR56","first-page":"1114","volume":"130","author":"T Narita","year":"2017","unstructured":"Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, et al. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma. Blood J Am Soc Hematol. 2017;130(9):1114\u201324.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"2141_CR57","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.leukres.2010.12.010","volume":"35","author":"SM Manohar","year":"2011","unstructured":"Manohar SM, Rathos MJ, Sonawane V, Rao SV, Joshi KS. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. Leuk Res. 2011;35(6):821\u201330.","journal-title":"Leuk Res"},{"issue":"12","key":"2141_CR58","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.3324\/haematol.2018.191395","volume":"103","author":"S Kinoshita","year":"2018","unstructured":"Kinoshita S, Ishida T, Ito A, Narita T, Masaki A, Suzuki S, et al. Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia\/lymphoma. Haematologica. 2018;103(12):2059.","journal-title":"Haematologica"},{"issue":"1","key":"2141_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13046-018-0704-8","volume":"37","author":"S Boffo","year":"2018","unstructured":"Boffo S, Damato A, Alfano L, Giordano A. CDK9 inhibitors in acute myeloid leukemia. J Exp Clin Cancer Res. 2018;37(1):36.","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"2141_CR60","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41416-024-02810-8","volume":"131","author":"R Rahman","year":"2024","unstructured":"Rahman R, Rahaman MH, Hanson AR, Choo N, Xie J, Townley SL, et al. CDK9 inhibition constrains multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. Br J Cancer. 2024;131(6):1092\u2013105.","journal-title":"Br J Cancer"},{"key":"2141_CR61","doi-asserted-by":"publisher","first-page":"678559","DOI":"10.3389\/fonc.2021.678559","volume":"11","author":"AT Anshabo","year":"2021","unstructured":"Anshabo AT, Milne R, Wang S, Albrecht H. CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents. Front Oncol. 2021;11:678559.","journal-title":"Front Oncol"},{"key":"2141_CR62","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Guti\u00e9rrez L, Delgado MD, Le\u00f3n J. MYC Oncogene Contributions to Release of Cell Cycle Brakes. Genes (Basel). 2019;10(3):244.","DOI":"10.3390\/genes10030244"},{"issue":"6","key":"2141_CR63","first-page":"1309","volume":"146","author":"S Krajewski","year":"1995","unstructured":"Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol. 1995;146(6):1309.","journal-title":"Am J Pathol"},{"issue":"2","key":"2141_CR64","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/jcb.26293","volume":"119","author":"LC Franco","year":"2018","unstructured":"Franco LC, Morales F, Boffo S, Giordano A. CDK9: A key player in cancer and other diseases. J Cell Biochem. 2018;119(2):1273\u201384.","journal-title":"J Cell Biochem"},{"issue":"2","key":"2141_CR65","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1101\/gad.182980.111","volume":"26","author":"SP Glaser","year":"2012","unstructured":"Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26(2):120\u20135.","journal-title":"Genes Dev"},{"issue":"6","key":"2141_CR66","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-13-0849","volume":"13","author":"T Yin","year":"2014","unstructured":"Yin T, Lallena MJ, Kreklau EL, Fales KR, Carballares S, Torrres R, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014;13(6):1442\u201356.","journal-title":"Mol Cancer Ther"},{"key":"2141_CR67","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1146\/annurev-pathol-011811-132434","volume":"7","author":"AG Muntean","year":"2012","unstructured":"Muntean AG, Hess JL. The pathogenesis of mixed-lineage leukemia. Annu Rev Pathol. 2012;7:283\u2013301.","journal-title":"Annu Rev Pathol"},{"key":"2141_CR68","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.biopha.2017.12.059","volume":"98","author":"S Safaei","year":"2018","unstructured":"Safaei S, Baradaran B, Hagh MF, Alivand MR, Talebi M, Gharibi T, et al. Double sword role of EZH2 in leukemia. Biomed Pharmacother. 2018;98:626\u201335.","journal-title":"Biomed Pharmacother"},{"issue":"47","key":"2141_CR69","doi-asserted-by":"publisher","first-page":"6766","DOI":"10.1038\/sj.onc.1210760","volume":"26","author":"B Argiropoulos","year":"2007","unstructured":"Argiropoulos B, Humphries RK. Hox genes in hematopoiesis and leukemogenesis. Oncogene. 2007;26(47):6766\u201376.","journal-title":"Oncogene"},{"issue":"3","key":"2141_CR70","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.molcel.2010.01.026","volume":"37","author":"C Lin","year":"2010","unstructured":"Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. AFF4, a component of the ELL\/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell. 2010;37(3):429\u201337.","journal-title":"Mol Cell"},{"issue":"14Supplement","key":"2141_CR71","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1158\/1538-7445.AM2016-3022","volume":"76","author":"A Scholz","year":"2016","unstructured":"Scholz A, Oellerich T, Hussain A, Lindner S, Luecking U, Walter AO, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb\/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). Cancer Res. 2016;76(14Supplement):3022.","journal-title":"Cancer Res"},{"issue":"21","key":"2141_CR72","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/cmdc.201700447","volume":"12","author":"U L\u00fccking","year":"2017","unstructured":"L\u00fccking U, Scholz A, Lienau P, Siemeister G, Kosemund D, Bohlmann R, et al. Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb\/CDK9 Inhibitor for the Treatment of Cancer. ChemMedChem. 2017;12(21):1776\u201393.","journal-title":"ChemMedChem"},{"issue":"4","key":"2141_CR73","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s10637-018-0661-2","volume":"37","author":"MH Rahaman","year":"2019","unstructured":"Rahaman MH, Yu Y, Zhong L, Adams J, Lam F, Li P, et al. CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Invest New Drugs. 2019;37(4):625\u201335.","journal-title":"Invest New Drugs"},{"issue":"7","key":"2141_CR74","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/leu.2014.40","volume":"28","author":"MP Garcia-Cuellar","year":"2014","unstructured":"Garcia-Cuellar MP, F\u00fcller E, M\u00e4thner E, Breitinger C, Hetzner K, Zeitlmann L, et al. Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia. Leukemia. 2014;28(7):1427\u201335.","journal-title":"Leukemia"},{"issue":"5","key":"2141_CR75","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/0008-5472.CAN-15-1070","volume":"76","author":"A Baker","year":"2016","unstructured":"Baker A, Gregory GP, Verbrugge I, Kats L, Hilton JJ, Vidacs E, et al. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Res. 2016;76(5):1158\u201369.","journal-title":"Cancer Res"},{"issue":"2","key":"2141_CR76","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/bloodadvances.2019000586","volume":"4","author":"H McCalmont","year":"2020","unstructured":"McCalmont H, Li KL, Jones L, Toubia J, Bray SC, Casolari DA, et al. Efficacy of combined CDK9\/BET inhibition in preclinical models of MLL-rearranged acute leukemia. Blood Adv. 2020;4(2):296\u2013300.","journal-title":"Blood Adv"},{"issue":"4","key":"2141_CR77","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"M Matsuoka","year":"2007","unstructured":"Matsuoka M, Jeang K-T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007;7(4):270\u201380.","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2141_CR78","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood-2016-09-741983","volume":"130","author":"T Narita","year":"2017","unstructured":"Narita T, Ishida T, Ito A, Masaki A, Kinoshita S, Suzuki S, et al. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia\/lymphoma. Blood. 2017;130(9):1114\u201324.","journal-title":"Blood"},{"key":"2141_CR79","doi-asserted-by":"publisher","first-page":"204062072093376","DOI":"10.1177\/2040620720933761","volume":"11","author":"P Johansson","year":"2020","unstructured":"Johansson P, Dierichs L, Klein-Hitpass L, Bergmann AK, M\u00f6llmann M, Menninger S, et al. Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. Therapeutic Adv Hematol. 2020;11:2040620720933761.","journal-title":"Therapeutic Adv Hematol"},{"issue":"4","key":"2141_CR80","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.clml.2018.02.003","volume":"18","author":"A O\u2019Reilly","year":"2018","unstructured":"O\u2019Reilly A, Murphy J, Rawe S, Garvey M. Chronic Lymphocytic Leukemia: A Review of Front-line Treatment Options, With a Focus on Elderly CLL Patients. Clin Lymphoma Myeloma Leuk. 2018;18(4):249\u201356.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"2141_CR81","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1182\/blood-2008-05-157131","volume":"112","author":"C Pepper","year":"2008","unstructured":"Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood. 2008;112(9):3807\u201317.","journal-title":"Blood"},{"issue":"16","key":"2141_CR82","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","volume":"118","author":"FK Stevenson","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118(16):4313\u201320.","journal-title":"Blood"},{"issue":"2","key":"2141_CR83","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood.V96.2.393","volume":"96","author":"S Kitada","year":"2000","unstructured":"Kitada S, Zapata JM, Andreeff M, Reed JC. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia. Blood. 2000;96(2):393\u20137.","journal-title":"Blood"},{"issue":"6","key":"2141_CR84","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1182\/blood-2011-12-400184","volume":"120","author":"E Mahoney","year":"2012","unstructured":"Mahoney E, Lucas DM, Gupta SV, Wagner AJ, Herman SE, Smith LL, et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. Blood. 2012;120(6):1262\u201373.","journal-title":"Blood"},{"issue":"6","key":"2141_CR85","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.clml.2014.09.007","volume":"15","author":"AV Desai","year":"2015","unstructured":"Desai AV, El-Bakkar H, Abdul-Hay M. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. Clin Lymphoma Myeloma Leuk. 2015;15(6):314\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"2141_CR86","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.leukres.2013.06.006","volume":"37","author":"DM Stephens","year":"2013","unstructured":"Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, et al. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res. 2013;37(10):1195\u20139.","journal-title":"Leuk Res"},{"key":"2141_CR87","doi-asserted-by":"crossref","unstructured":"Nguyen L, Papenhausen P, Shao H. The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects. Genes (Basel). 2017;8(4):116.","DOI":"10.3390\/genes8040116"},{"issue":"1","key":"2141_CR88","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1365-2559.2010.03706.x","volume":"58","author":"SE Coupland","year":"2011","unstructured":"Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology. 2011;58(1):69\u201380.","journal-title":"Histopathology"},{"issue":"3","key":"2141_CR89","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/PAS.0000000000000365","volume":"39","author":"KM Chisholm","year":"2015","unstructured":"Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39(3):294\u2013303.","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"2141_CR90","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminhematol.2015.01.009","volume":"52","author":"K Karube","year":"2015","unstructured":"Karube K, Campo E. MYC alterations in diffuse large B-cell lymphomas. Semin Hematol. 2015;52(2):97\u2013106.","journal-title":"Semin Hematol"},{"issue":"17","key":"2141_CR91","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","volume":"114","author":"KJ Savage","year":"2009","unstructured":"Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533\u20137.","journal-title":"Blood"},{"issue":"42","key":"2141_CR92","doi-asserted-by":"publisher","first-page":"40156","DOI":"10.1074\/jbc.M207441200","volume":"277","author":"SR Eberhardy","year":"2002","unstructured":"Eberhardy SR, Farnham PJ. Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J Biol Chem. 2002;277(42):40156\u201362.","journal-title":"J Biol Chem"},{"issue":"36","key":"2141_CR93","doi-asserted-by":"publisher","first-page":"5707","DOI":"10.1038\/sj.onc.1206800","volume":"22","author":"S Kanazawa","year":"2003","unstructured":"Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene. 2003;22(36):5707\u201311.","journal-title":"Oncogene"},{"issue":"22","key":"2141_CR94","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1182\/blood.V128.22.289.289","volume":"128","author":"T Rowland","year":"2016","unstructured":"Rowland T, Paiva C, Rowley J, Chen A, Drew L, Hurlin P, et al. Selective targeting cyclin-dependent kinase-9 (CDK9) downmodulates c-MYC and induces apoptosis in diffuse large B-cell lymphoma (DLBCL) cells. Blood. 2016;128(22):289.","journal-title":"Blood"},{"issue":"10272","key":"2141_CR95","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"11","key":"2141_CR96","first-page":"3527","volume":"8","author":"I Gojo","year":"2002","unstructured":"Gojo I, Zhang B, Fenton RG. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin Cancer Res. 2002;8(11):3527\u201338.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2141_CR97","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13058-019-1161-9","volume":"21","author":"RP McLaughlin","year":"2019","unstructured":"McLaughlin RP, He J, van der Noord VE, Redel J, Foekens JA, Martens JWM, et al. A kinase inhibitor screen identifies a dual cdc7\/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Res. 2019;21(1):77.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"2141_CR98","doi-asserted-by":"publisher","first-page":"e0232068","DOI":"10.1371\/journal.pone.0232068","volume":"15","author":"SL Lim","year":"2020","unstructured":"Lim SL, Xu L, Han BC, Shyamsunder P, Chng WJ, Koeffler HP. Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor. PLoS ONE. 2020;15(6):e0232068.","journal-title":"PLoS ONE"},{"issue":"4","key":"2141_CR99","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s12032-021-01636-1","volume":"39","author":"J Borowczak","year":"2022","unstructured":"Borowczak J, Szczerbowski K, Ahmadi N, Szylberg \u0141. CDK9 inhibitors in multiple myeloma: a review of progress and perspectives. Med Oncol. 2022;39(4):39.","journal-title":"Med Oncol"},{"issue":"3","key":"2141_CR100","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1023\/A:1006353008903","volume":"17","author":"AM Senderowicz","year":"1999","unstructured":"Senderowicz AM. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Invest New Drugs. 1999;17(3):313\u201320.","journal-title":"Invest New Drugs"},{"key":"2141_CR101","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jbiotec.2015.02.032","volume":"202","author":"HS Khalil","year":"2015","unstructured":"Khalil HS, Mitev V, Vlaykova T, Cavicchi L, Zhelev N. Discovery and development of Seliciclib. How systems biology approaches can lead to better drug performance. J Biotechnol. 2015;202:40\u20139.","journal-title":"J Biotechnol"},{"issue":"11","key":"2141_CR102","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.3324\/haematol.2012.062539","volume":"97","author":"JE Karp","year":"2012","unstructured":"Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, et al. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Haematologica. 2012;97(11):1736\u201342.","journal-title":"Haematologica"},{"issue":"4","key":"2141_CR103","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/COC.0b013e3181b2043f","volume":"33","author":"HM Fekrazad","year":"2010","unstructured":"Fekrazad HM, Verschraegen CF, Royce M, Smith HO, Chyi Lee F, Rabinowitz I. A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer. Am J Clin Oncol. 2010;33(4):393\u20137.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"2141_CR104","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2013.11.020","volume":"83","author":"JJ Stephenson","year":"2014","unstructured":"Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, et al. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer. 2014;83(2):219\u201323.","journal-title":"Lung Cancer"},{"issue":"3","key":"2141_CR105","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","volume":"125","author":"SK Kumar","year":"2015","unstructured":"Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, et al. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. Blood. 2015;125(3):443\u20138.","journal-title":"Blood"},{"key":"2141_CR106","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.3389\/fphar.2020.01230","volume":"11","author":"M Cassandri","year":"2020","unstructured":"Cassandri M, Fioravanti R, Pomella S, Valente S, Rotili D, Del Baldo G, et al. CDK9 as a Valuable Target in Cancer: From Natural Compounds Inhibitors to Current Treatment in Pediatric Soft Tissue Sarcomas. Front Pharmacol. 2020;11:1230.","journal-title":"Front Pharmacol"},{"issue":"12","key":"2141_CR107","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","volume":"39","author":"JF Zeidner","year":"2015","unstructured":"Zeidner JF, Karp JE. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res. 2015;39(12):1312\u20138.","journal-title":"Leuk Res"},{"issue":"5","key":"2141_CR108","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/ijc.10738","volume":"102","author":"SJ McClue","year":"2002","unstructured":"McClue SJ, Blake D, Clarke R, Cowan A, Cummings L, Fischer PM, et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer. 2002;102(5):463\u20138.","journal-title":"Int J Cancer"},{"issue":"1\u20132","key":"2141_CR109","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1432-1033.1997.t01-2-00527.x","volume":"243","author":"L Meijer","year":"1997","unstructured":"Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem. 1997;243(1\u20132):527\u201336.","journal-title":"Eur J Biochem"},{"issue":"17","key":"2141_CR110","doi-asserted-by":"publisher","first-page":"7717","DOI":"10.1158\/0008-5472.CAN-05-0347","volume":"65","author":"S Mohapatra","year":"2005","unstructured":"Mohapatra S, Chu B, Zhao X, Pledger WJ. Accumulation of p53 and reductions in XIAP abundance promote the apoptosis of prostate cancer cells. Cancer Res. 2005;65(17):7717\u201323.","journal-title":"Cancer Res"},{"key":"2141_CR111","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","volume":"173","author":"SR Whittaker","year":"2017","unstructured":"Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017;173:83\u2013105.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"2141_CR112","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1535-7163.MCT-10-0324","volume":"9","author":"D Parry","year":"2010","unstructured":"Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9(8):2344\u201353.","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"2141_CR113","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/leu.2012.144","volume":"26","author":"AJ Johnson","year":"2012","unstructured":"Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia. 2012;26(12):2554\u20137.","journal-title":"Leukemia"},{"issue":"21","key":"2141_CR114","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1182\/blood.V116.21.3981.3981","volume":"116","author":"M Sadowska","year":"2010","unstructured":"Sadowska M, Muvarak N, Lapidus RG, Sausville EA, Bannerji R, Gojo I. Single agent activity of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in acute myeloid and lymphoid leukemia cells. Blood. 2010;116(21):3981.","journal-title":"Blood"},{"issue":"7","key":"2141_CR115","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/leu.2015.31","volume":"29","author":"J Flynn","year":"2015","unstructured":"Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015;29(7):1524\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"2141_CR116","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1172\/JCI94586","volume":"128","author":"DMS Hossain","year":"2018","unstructured":"Hossain DMS, Javaid S, Cai M, Zhang C, Sawant A, Hinton M, et al. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest. 2018;128(2):644\u201354.","journal-title":"J Clin Invest"},{"issue":"4","key":"2141_CR117","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-008-0921-5","volume":"64","author":"A Conroy","year":"2009","unstructured":"Conroy A, Stockett DE, Walker D, Arkin MR, Hoch U, Fox JA, et al. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009;64(4):723\u201332.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"2141_CR118","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2009.26.1347","volume":"28","author":"WG Tong","year":"2010","unstructured":"Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol. 2010;28(18):3015\u201322.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2141_CR119","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson CM, Jiang B, Erb MA, Liang Y, Doctor ZM, Zhang Z, et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat Chem Biol. 2018;14(2):163\u201370.","journal-title":"Nat Chem Biol"},{"issue":"8","key":"2141_CR120","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/j.jid.2020.12.035","volume":"141","author":"SM Guhan","year":"2021","unstructured":"Guhan SM, Shaughnessy M, Rajadurai A, Taylor M, Kumar R, Ji Z, et al. The Molecular Context of Vulnerability for CDK9 Suppression in Triple Wild-Type Melanoma. J Invest Dermatol. 2021;141(8):2018\u2013e274.","journal-title":"J Invest Dermatol"},{"key":"2141_CR121","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/1538-7445.AM2017-984","volume":"77","author":"U Luecking","year":"2017","unstructured":"Luecking U, Scholz A, Kosemund D, Bohlmann R, Briem H, Lienau P, et al. Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops. Cancer Res. 2017;77:984.","journal-title":"Cancer Res"},{"key":"2141_CR122","doi-asserted-by":"publisher","first-page":"204062072093376","DOI":"10.1177\/2040620720933761","volume":"11","author":"P Johansson","year":"2020","unstructured":"Johansson P, Dierichs L, Klein-Hitpass L, Bergmann AK, M\u00f6llmann M, Menninger S, et al. Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia. Ther Adv Hematol. 2020;11:2040620720933761.","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"2141_CR123","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.21873\/anticanres.15416","volume":"41","author":"JP Ruff","year":"2021","unstructured":"Ruff JP, Kretz AL, Kornmann M, Henne-Bruns D, Lemke J, Traub B. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death. Anticancer Res. 2021;41(12):5973\u201385.","journal-title":"Anticancer Res"},{"issue":"4","key":"2141_CR124","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","volume":"26","author":"J Cidado","year":"2020","unstructured":"Cidado J, Boiko S, Proia T, Ferguson D, Criscione SW, San Martin M, et al. AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. Clin Cancer Res. 2020;26(4):922\u201334.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2141_CR125","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1182\/blood.2020008528","volume":"137","author":"S Boiko","year":"2021","unstructured":"Boiko S, Proia T, San Martin M, Gregory GP, Wu MM, Aryal N, et al. Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas. Blood. 2021;137(21):2947\u201357.","journal-title":"Blood"},{"issue":"4","key":"2141_CR126","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1158\/1078-0432.CCR-19-3670","volume":"26","author":"C Alcon","year":"2020","unstructured":"Alcon C, Manzano-Mu\u00f1oz A, Montero J. A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies. Clin Cancer Res. 2020;26(4):761\u20133.","journal-title":"Clin Cancer Res"},{"issue":"15suppl","key":"2141_CR127","doi-asserted-by":"publisher","first-page":"TPS7588","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7588","volume":"36","author":"S Rule","year":"2018","unstructured":"Rule S, Kater AP, Br\u00fcmmendorf TH, Fegan C, Kaiser M, Radford JA, et al. A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies. J Clin Oncol. 2018;36(15suppl):TPS7588\u2013TPS.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2141_CR128","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13148-023-01617-3","volume":"16","author":"H Zhang","year":"2024","unstructured":"Zhang H, Huang C, Gordon J, Yu S, Morton G, Childers W, et al. MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer. Clin Epigenetics. 2024;16(1):3.","journal-title":"Clin Epigenetics"},{"issue":"14","key":"2141_CR129","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.1007\/s00018-021-03878-8","volume":"78","author":"S Egloff","year":"2021","unstructured":"Egloff S. CDK9 keeps RNA polymerase II on track. Cell Mol Life Sci. 2021;78(14):5543\u201367.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"2141_CR130","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s13402-025-01154-6","volume":"49","author":"VE van der Noord","year":"2026","unstructured":"van der Noord VE, McLaughlin RP, Karuntu JS, He J, Timmermans AM, Basnet SKC, et al. Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition. Cell Oncol (Dordr). 2026;49(1):20.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"2141_CR131","doi-asserted-by":"publisher","first-page":"2219470","DOI":"10.1080\/15384047.2023.2219470","volume":"24","author":"L Xiao","year":"2023","unstructured":"Xiao L, Liu Y, Chen H, Shen L. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. Cancer Biol Ther. 2023;24(1):2219470.","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"2141_CR132","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1016\/j.apsb.2023.05.026","volume":"13","author":"C Hu","year":"2023","unstructured":"Hu C, Shen L, Zou F, Wu Y, Wang B, Wang A, et al. Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy. Acta Pharm Sin B. 2023;13(9):3694\u2013707.","journal-title":"Acta Pharm Sin B"},{"key":"2141_CR133","doi-asserted-by":"publisher","first-page":"e06535","DOI":"10.7554\/eLife.06535","volume":"4","author":"H Lu","year":"2015","unstructured":"Lu H, Xue Y, Yu GK, Arias C, Lin J, Fong S, et al. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism. Elife. 2015;4:e06535.","journal-title":"Elife"},{"key":"2141_CR134","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbrc.2023.05.114","volume":"671","author":"R Liu","year":"2023","unstructured":"Liu R. Brd4-dependent CDK9 expression induction upon sustained pharmacological inhibition of P-TEFb kinase activity. Biochem Biophys Res Commun. 2023;671:75\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"15","key":"2141_CR135","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/cancers13153906","volume":"13","author":"J Padmanabhan","year":"2021","unstructured":"Padmanabhan J, Saha B, Powell C, Mo Q, Perez BA, Chellappan S. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Cancers. 2021;13(15):3906.","journal-title":"Cancers"},{"issue":"1","key":"2141_CR136","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12943-023-01762-6","volume":"22","author":"E Thieme","year":"2023","unstructured":"Thieme E, Bruss N, Sun D, Dominguez EC, Coleman D, Liu T, et al. CDK9 inhibition induces epigenetic reprogramming revealing strategies to circumvent resistance in lymphoma. Mol Cancer. 2023;22(1):64.","journal-title":"Mol Cancer"},{"issue":"1","key":"2141_CR137","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-024-00484-9","volume":"13","author":"F Yan","year":"2024","unstructured":"Yan F, Jiang V, Jordan A, Che Y, Liu Y, Cai Q, et al. The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma. Experimental Hematol Oncol. 2024;13(1):14.","journal-title":"Experimental Hematol Oncol"},{"issue":"7","key":"2141_CR138","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/13543784.2020.1789588","volume":"29","author":"T Satta","year":"2020","unstructured":"Satta T, Grant S. Enhancing venetoclax activity in hematological malignancies. Expert Opin Investig Drugs. 2020;29(7):697\u2013708.","journal-title":"Expert Opin Investig Drugs"},{"key":"2141_CR139","doi-asserted-by":"crossref","unstructured":"George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK et al. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. Cancers (Basel). 2020;12(5):1328.","DOI":"10.3390\/cancers12051328"},{"issue":"3","key":"2141_CR140","doi-asserted-by":"publisher","first-page":"100108","DOI":"10.1016\/j.bneo.2025.100108","volume":"2","author":"Y Alvarado-Valero","year":"2025","unstructured":"Alvarado-Valero Y, Cook RJ, Dinner SN, Keng M, Begna KH, Javidi-Sharifi N, et al. The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed\/refractory acute myeloid leukemia. Blood Neoplasia. 2025;2(3):100108.","journal-title":"Blood Neoplasia"},{"issue":"1","key":"2141_CR141","doi-asserted-by":"publisher","first-page":"100050","DOI":"10.1016\/j.bneo.2024.100050","volume":"2","author":"S Tran","year":"2025","unstructured":"Tran S, Sipila P, Frigault MM, Stelte-Ludwig B, Johnson AJ, Birkett J, et al. Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. Blood Neoplasia. 2025;2(1):100050.","journal-title":"Blood Neoplasia"},{"issue":"Supplement 1","key":"2141_CR142","doi-asserted-by":"publisher","first-page":"5783","DOI":"10.1182\/blood-2023-190093","volume":"142","author":"N Fultang","year":"2023","unstructured":"Fultang N, Schwab AM, McAneny-Droz S, Heiser D, Scherle PA, Bhagwat N. PRT2527, a Novel Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, Has Potent Antitumor Activity in Combination with BTK and BCL2 Inhibition in Various Lymphoid Malignancies. Blood. 2023;142(Supplement 1):5783.","journal-title":"Blood"},{"key":"2141_CR143","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/978-3-319-91439-8_11","volume":"212","author":"A Scheffold","year":"2018","unstructured":"Scheffold A, Jebaraj BMC, Stilgenbauer S, Venetoclax. Targeting BCL2 in Hematological Cancers. Recent Results Cancer Res. 2018;212:215\u201342.","journal-title":"Recent Results Cancer Res"},{"issue":"1","key":"2141_CR144","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/neuonc\/noad143","volume":"26","author":"I Bhutada","year":"2024","unstructured":"Bhutada I, Khambati F, Cheng SY, Tiek DM, Duckett D, Lawrence H, et al. CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity. Neuro Oncol. 2024;26(1):70\u201384.","journal-title":"Neuro Oncol"},{"key":"2141_CR145","doi-asserted-by":"crossref","unstructured":"Pimentel JM, Zhou JY, Wu GS. The Role of TRAIL in Apoptosis and Immunosurveillance in Cancer. Cancers (Basel). 2023;15(10):2752.","DOI":"10.3390\/cancers15102752"},{"key":"2141_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-11-211","volume":"11","author":"HO Ohnstad","year":"2011","unstructured":"Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, et al. MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines. BMC Cancer. 2011;11:211:1\u201311.","journal-title":"BMC Cancer"},{"issue":"20","key":"2141_CR147","doi-asserted-by":"publisher","first-page":"21172","DOI":"10.1021\/acs.jmedchem.5c01111","volume":"68","author":"L Ma","year":"2025","unstructured":"Ma L, Xie L, Wang Y, Guan X, Zhang Y, Guo H, et al. Discovery of dCDK9-202 as a Highly Potent and Selective PROTAC CDK9 Degrader with Strong In Vivo Antitumor Activity. J Med Chem. 2025;68(20):21172\u201386.","journal-title":"J Med Chem"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02141-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02141-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02141-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:01:50Z","timestamp":1784858510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02141-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":147,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2141"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02141-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be considered as a potential conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants or clinical interventions.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"278"}}